TITLE:
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

CONDITION:
Schizophrenic Disorders

INTERVENTION:
Intramuscular Olanzapine Depot

SUMMARY:

      This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine
      depot works compared to oral olanzapine; evaluate the safety and tolerability of IM
      olanzapine depot compared to oral olanzapine; evaluate different doses of IM olanzapine
      depot; and determine the blood levels of IM olanzapine depot in patients at different points
      in time after an injection.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Patients must have schizophrenia

          -  Patients must be clinically stable on antipsychotic medication

          -  Patients must be retrospectively judged by investigators, based on clinical interview
             and impression, to have been stable (with respect to their symptoms of schizophrenia)
             for at least 4 weeks entry into the study

          -  Patients must be an outpatient and have BPRS positive items scores of 4 or less to
             enter the study

          -  Female patients of childbearing potential must be using a medically accepted means of
             contraception.

        Exclusion Criteria:

          -  Patients must not have participated in a clinical trial of another investigational
             drug, including olanzapine, within 1 month (30 days) prior to study entry.

          -  Female patients must not be pregnant or breast-feeding

          -  Patients must not be experiencing acute, serious, or unstable medical conditions
             other than schizophrenia

          -  Patients must not require concomitant treatment with any other medication with
             primarily central nervous system activity, including antidepressants, mood
             stabilizers, and anticonvulsants.

          -  Patients must not have a substance (except nicotine or caffeine) dependence within
             the past 30 days
      
